COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #196 of 237
11/28 N/A
Ruiz et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106247 (Peer Reviewed)
Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19
Source   PDF   Share   Tweet
HCQ lung pharmacokinetic study confirming that lung concentrations can be much higher than plasma.
The median lung epithelial lining fluid concentration was 38 times higher than plasma concentrations. 22 COVID-19 patients, median age 59.5.
Dosage determinations in studies assuming equilibrium between epithelium and plasma concentrations may lead to overly high dosages.
Authors find the median ELF concentration of HCQ above the maximum EC50 value for 400 mg x 1 /day and 200 mg x 3 /day, 7-12 days after treatment initiation.

Ruiz et al., 11/28/2020, peer-reviewed, 14 authors.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit